User profiles for T Andre
Thierry AndréHôpital Saint Antoine Verified email at aphp.fr Cited by 59765 |
Participation in extracurricular activities in secondary school: What is known, what needs to be known?
A Holland, T Andre - Review of educational research, 1987 - journals.sagepub.com
The paper reviews literature relating to extracurricular participation and adolescent
development. Five areas are described: personal-social characteristics, academic achievement, …
development. Five areas are described: personal-social characteristics, academic achievement, …
Five insights from the global burden of disease study 2019
…, D Anderlini, JA Anderson, T Andrei, CL Andrei… - The Lancet, 2020 - thelancet.com
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a
rules-based synthesis of the available evidence on levels and trends in health outcomes, a …
rules-based synthesis of the available evidence on levels and trends in health outcomes, a …
[HTML][HTML] MicroScale Thermophoresis: Interaction analysis and beyond
M Jerabek-Willemsen, T André, R Wanner… - Journal of Molecular …, 2014 - Elsevier
… T-Jump and thermophoresis signals are highlighted. (B) Thermophoresis signal from experiments
equivalent to those shown in (A). Error bars = sd; n = 3. (C) T-… demonstrate that T-jump …
equivalent to those shown in (A). Error bars = sd; n = 3. (C) T-… demonstrate that T-jump …
[HTML][HTML] Pembrolizumab in microsatellite-instability–high advanced colorectal cancer
T André, KK Shiu, TW Kim, BV Jensen… - … England Journal of …, 2020 - Mass Medical Soc
Background Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high
(MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The …
(MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The …
[HTML][HTML] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T André, C Boni, L Mounedji-Boudiaf… - … England Journal of …, 2004 - Mass Medical Soc
… The most important prognostic indicator of survival in early colon cancer is the stage of the
tumor (T, according to the tumor–node–metastasis [TNM] classification), determined by the …
tumor (T, according to the tumor–node–metastasis [TNM] classification), determined by the …
[HTML][HTML] Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
…, GGH Amul, D Anderlini, CL Andrei, T Andrei… - The lancet, 2020 - thelancet.com
Background In an era of shifting global agendas and expanded emphasis on non-communicable
diseases and injuries along with communicable diseases, sound evidence on trends …
diseases and injuries along with communicable diseases, sound evidence on trends …
[HTML][HTML] Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Background Rigorous analysis of levels and trends in exposure to leading risk factors and
quantification of their effect on human health are important to identify where public health is …
quantification of their effect on human health are important to identify where public health is …
[PDF][PDF] Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
T André, C Boni, M Navarro, J Tabernero, T Hickish… - J clin oncol, 2009 - academia.edu
Purpose Three-year disease-free survival (DFS) was significantly improved in patients who
had undergone resection with curative intent for stage II or III colon cancer who received …
had undergone resection with curative intent for stage II or III colon cancer who received …
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch …
T André, A De Gramont, D Vernerey… - Journal of Clinical …, 2015 - ascopubs.org
… Means and proportions were compared using the t test and χ 2 test (or Fisher exact test),
respectively. OS was calculated from the date of random assignment to the date of death as a …
respectively. OS was calculated from the date of random assignment to the date of death as a …
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients …
…, AF Sobrero, M Ducreux, Y Hotko, T André… - Journal of clinical …, 2010 - ascopubs.org
Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR)
monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory …
monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory …